SAPCD2 has been reported to be upregulated in various kinds of tumors, including breast cancer (34), gastric cancer (11), hepatocellular carcinoma (17), colorectal carcinoma (14), glioblastoma (19), nasopharyngeal carcinoma (15), lung adenocarcinoma (16), melanoma (18), and renal cell cancer (20). This evidence concerns the gene SAPCD2 and renal cell adenocarcinoma.